NUVB
NUVB clinical trials: Nuvation Bio Inc.
Every trial on ClinicalTrials.gov where Nuvation Bio Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 22
- Trials linked
- 19
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
NUVB on the catalyst calendar · NUVB registry changes
- Primary completion Dec 1, 2028Sponsor estimatePhase 3NCT05303519SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Nuvation Bio Inc. · GliomaRecruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2030Sponsor estimatePhase 2NCT07703436Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to...Nuvation Bio Inc. · Grade 2 IDH1-mutant GliomaRecruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2027Sponsor estimatePhase 1NCT07742384Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNuvation Bio Inc. · Healthy Adult ParticipantsNot yet recruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2029Sponsor estimatePhase 3NCT07712757Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant GliomaNuvation Bio Inc. · Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 MutationNot yet recruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2030Sponsor estimatePhase 3NCT07154706Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)Nuvation Bio Inc. · Non-small Cell Lung Cancer (NSCLC)RecruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 3NCT06564324A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung...Nuvation Bio Inc. · Non Small Cell Lung CancerRecruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 7, 2024ActualPhase 2NCT04395677A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNuvation Bio Inc. · Non Small Cell Lung CancerActive, not recruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2024ActualPhase 2NCT04617054Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNuvation Bio Inc. · Solid TumorTerminatedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1/Phase 2NCT06334432Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNuvation Bio Inc. · Advanced Solid TumorActive, not recruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 11, 2025ActualPhase 2NCT04919811Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNuvation Bio Inc. · Non Small Cell Lung CancerActive, not recruitingNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06841874Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLCNuvation Bio Inc. · Lung NeoplasmsNo longer availableNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2024ActualPhase 1NCT05252390NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNuvation Bio Inc. · Advanced Solid TumorTerminatedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2019ActualPhase 1NCT02279433A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bNuvation Bio Inc. · Solid TumorsCompletedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2023ActualPhase 1NCT05609929Study the Effect of Omeprazole on AB-106 PharmacokineticsNuvation Bio Inc. · Pharmacokinetic StudyCompletedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2021ActualPhase 1NCT05357911A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinNuvation Bio Inc. · Solid TumorCompletedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2021ActualPhase 1NCT05357820A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKNuvation Bio Inc. · Solid TumorCompletedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2022ActualPhase 1NCT04541225Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNuvation Bio Inc. · GliomaTerminatedNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2025Sponsor estimatePhase 1/Phase 2NCT05191004Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCNuvation Bio Inc. · Advanced Breast CancerWithdrawnNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2025Sponsor estimatePhase 1/Phase 2NCT05191017Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCNuvation Bio Inc. · Prostate CancerWithdrawnNUVBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 2NCT07832123Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II StudyUniversity of Zurich · Glioma : Oligodendroglioma or AstrocytomaNot yet recruitingNUVBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2025ActualEarly Phase 1NCT05577416A Study of AB-218 in Patients With IDH1 Mutated Low Grade GliomaMelbourne Health · GliomaCompletedNUVBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimateNo phase registeredNCT04151342CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)University Health Network, Toronto · Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 22 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner